Индивидуальное дозирование ингибиторов фосфодиэстеразы 5-го типа как путь повышения эффективности и безопасности медикаментозного лечения эректильной дисфункции

1. Бакшеев В.И., Коломоец Н.М., Гончарук А.И. Синдром эректильной дисфункции в практике терапевта. Клин. медицина. 2005; 3: 16–23.
2. Верткин А.Л. Эректильная дисфункция в практике врача-кардиолога. РМЖ. 2003; 19: 1107–13.
3. Верткин А.Л., Лоран О.Б., Тополянский А.В. и др. Эректильная дисфункция у кардиологических и терапевтических пациентов. РМЖ. 2001; 25: 1308–17.
4. Рафальский В.В., Багликов А.Н. Подходы к рациональному выбору ингибиторов фосфодиэстеразы 5-го типа у пациентов с сердечно-сосудистыми заболеваниями. Проблемы эндокринологии. 2010; 6: 63–72.
5. Balon R, Yeragani VK, Pohl R, Ramesh C. Sexual dysfunction during antidepressant treatment. J Clin Psychiatry 1993; 54: 209–12.
6. Billups KL, Edina MN, Kaiser D et al. Erectile dysfunction as an early indicator of systemic oxidative stress and endothelial cell dysfunction. J Urol 2003; 169: 323.
7. Carson CC, Rajfer J, Eardley I et al. The efficacy and safety of tadalafil: an update. Br J Urol Int 2004: 93: 1276–81.
8. Ferrario CM, Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens 2002; 4 (6): 424–32.
9. Fink HA, Mac Donald R, Rutks IR et al. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002: 162: 1349–60.
10. Fogari R, Zoppi A. Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr Hypertens Rep 2002; 4 (3): 202–10.
11. Fogari R, Corradi I, Poletti L et al. Sexual activity in hypertensive males treated with valsartan or carvedilol. A cross-over study. J Hypertens 1999; 17 (Suppl. 3): S65.
12. Guay AT. Erectile dysfunction – are you prepared to discuss it? Postgrad Med 1995; 97: 127–43.
13. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622.
14. Jackson G. Simvastatin and impotence [letter]. BMJ 1997; 
p. 315-31.
15. James CW, Wu TS, McNelis KC. Sexual Dysfunction Secondary to Gemfibrozil. Pharmacotherapy 2002; 22 (2): 123–5.
16. Johannes CB, Araujo AB, Feldman HA et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. Urol 2000; 163: 460–3.
17. Khan MA, Thompson CS, Sullivan ME et al. The role of prostaglandins in the aetiology and treatment of erectile dysfunction. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 169–74.
18. Khan MA, Calvert RC, Sullivan ME et al. Normal and pathological erectile function: the potential clinical role of endothelin-1 antagonists. Curr Drug Targets 2000; 1: 247–260.
19. Khan MA, Morgan RJ, Mikhailidis DP. The choice of antihypertensive drugs in patients with erectile dysfunction. Curr Med Res Opin 2002; 18 (2): 103–7.
20. Kleinman KP, Feldman HA, Johannes CB et al. A new surrogate variable for erectile dysfunction status in the Massachusetts Male Aging Study. J Clin Epidemiol 2000; 53: 71–8.
21. Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol 2000; 86: 57F.
22. Kloner RA, Mitchell MI, Bedding A, Emmick J. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil. J Urol 2002; 167 (4): 176–7.
23. Ko DT, Hebert PR, Coffey CS et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288 (3): 351–7.
24. Llisterri JL, Lozano Vidal JV, Aznar Vicente J et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321 (5): 336–41.
25. Markou S, Perimenis P, Gyftopoulos K et al. Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports. Int J Impot Res 2004; 16 (6): 470–8.
26. Mickley H. Incidence and treatment of sexual dysfunction in heart disease. Ugeskr Laeger 2002; 164 (41): 4760–4.
27. Nicolosi A, Laumann EO, Glasser DB et al. Global Study of Sexual Attitudes and Behaviors Investigators’ Group. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. J Urol 2004; 64: 991–7.
28. NIH Consensus Conference on Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83–90.
29. O’Keefe M, Hunt DK. Assessment and treatment of impotence. 
Med Clin North Am 1995; 79: 415–34.
30. Olsson AM, Speakman MJ, Dinsmore WW et al. Sildenafil citrate (Viagra) is effective and well tolerated for treating erectile dysfunction of psychogenic or mixed aetiology. Int J Clin Pract 2000; 54 (9): 561–6.
31. Prisant L.M. Fixed low-dose combination in first-line treatment of hypertension. J Hypertens 2002; 20 (Suppl. 1): S11–9.
32. Ralph D, McNicholas T. UK management guidelines for erectile dysfunction. BMJ 2000; 321 (19): 499–503.
33. Slag MF, Morley JE, Elson MK et al. Impotence in medical clinic outpatients. JAMA 1983; 249: 1736–40.
34. Solomon H, Han JW, Jackson G. Erectile dysfunction and the cardiovascular patients: endothelial dysfunction is the common denominator. Heart 2003; 89: 251–3.
35. Stewart C, Hogan S. Evidence based review of medicines for sexual dysfunction in men: A report commissioned by the New Zealand Accident Compensation Corporation (ACC). NZHTA Report 2004; 
7 (4).
36. Webb DJ, Muirhead GJ, Wulff M et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angin. J Am Coll Cardiol 2000; 36: 25.

М.В.Пчелинцев

ГБОУ ВПО Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова 
Минздрава России